Asphalion expert Núria García participated last week in the 2nd Annual PragmaTIL Consortium Meeting in Amsterdam, hosted by the Netherlands Cancer Institute (NKI). This two-day event brought together partners from across Europe to align on strategy, share progress, and strengthen collaboration in the advancement of Tumor-Infiltrating Lymphocyte (TIL) therapy for cancer patients.
As the regulatory partner in this EU-funded Horizon Europe project, Asphalion is leading the regulatory work package, focusing on the submission of the clinical trial application and the safety management plan. Our team supports the project with expert clinical and regulatory strategies to ensure compliance, accelerate patient recruitment, and help bring innovative therapies to patients safely and efficiently.
Meeting highlights included:
- Clinical trial updates and patient recruitment milestones
- Patient involvement as co-researchers in the study
- Strategy planning for long-term patient-reported outcomes (PROs)
- Considerations around health economics and sustainability
- Tour of GMP facilities at NKI, showcasing TIL manufacturing processes
- Collaborative discussions on broader trial implementation
We thank the Netherlands Cancer Institute for hosting the meeting and all consortium members for their commitment to advancing cancer care through this project.
For regulatory support in your EU-funded projects, please contact us at [email protected]
